ASRS 2023: What research is most exciting? Our interviewees give their opinions.

News
Video

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!

The American Society of Retina Specialists held their 2023 annual meeting in Seattle, Washington. At the event, we asked attendees, "What research here do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin PhD, and Carl Danzig, MD had to say!

Video Transcript

Editor's note - This transcript has been edited for clarity.

Aaron Lee, MD: There's a large number of [topics], especially with the new therapeutics that are coming online with dry AMD and wet AMD. We now have a lot more choices than ever before. I think what's going to be confusing and the field will struggle with is understanding what drug to use when. And that's why again, I think, hopefully, artificial intelligence will be one of the methods that can help us discern which therapy might be best for a given patient.

Megan Baldwin, PhD: Well, look, I'm, I'm a researcher by background. I've seen a number of different presentations at this conference and also at the Ophthalmology Innovations Summit, which was earlier in the week. And I'm really excited by some of the new research coming through on mitochondrial approaches. Some of the regenerative medicine approaches that I think in the longer term are really based on really exciting science. And I think in the longer term, if we can start to look at novel mechanisms, we are going to have much better outcomes for patients overall, I think some of that early research has got a long way to go. But it's great to see the fruition of a lot of basic academic research now starting to be translated into new therapeutics. And I like to think that OPT-302 and our approach is just 1 example of that. And we are now in Phase 3 clinical development, but it came from really great scientific research that we've been working on for many, many years. And I see the parallels with some of the early research coming through now as well.

Carl Danzig, MD: I'm very interested in the Aviceda program. Carl Regillo just had an excellent presentation this morning. It's very early phase, but we're looking at the potential to treat GA patients and also have an effect on neovascularisation. So I find that very exciting.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.